Globally, opioid overdose deaths are more common than you think. It is one of the most important public health concerns, ...

SAN DIEGO, CA / ACCESS Newswire / July 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical innovator focused on redefining opioid safety, ...

Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswire / April 7, 2026 / Ensysce Biosciences, Inc.

A novel mu-opioid receptor agonist showed strong analgesia without respiratory depression, tolerance, or significant ...

The FDA is requiring manufacturers of opioid pain medications to update safety labels to better emphasize risks linked to their long-term use, the agency announced in a new Drug Safety Communication.

Approximately 80% of patients reported taking an analgesic like ibuprofen for dental pain, with about 10% of them accidentally overdosing on it. The study was published on January 17 in Basic and ...

Findings from postmarketing studies showed long-term opioid use was associated with serious risks including misuse, addiction, and overdose. The Food and Drug Administration (FDA) is requiring ...

National Institutes of Health researchers have identified a compound called N-desethyl-fluornitrazene, or DFNZ, that ...

~ FDA and Ensysce Aligned on Collaborative Approach to Ensure Product's Full Safety Benefits are Recognized ~ PF614-MPAR has earned the FDA's prestigious Breakthrough Therapy designation and is ...